About SIGNABLOK, INC.
SignaBlok, Inc. is a biopharmaceutical company founded in 2009, focused on developing novel targeted therapeutics and delivery nanosystems using its proprietary SCHOOL platform for macrophage modulation and imaging in various inflammatory and immune-related diseases.
Development of novel targeted therapeuticsCreation of multifunctional nanosystems for drug deliveryMacrophage imaging and modulation technologiesResearch in inflammation-associated diseases
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to SIGNABLOK, INC. right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.